EUCTR2004-004378-10-GB进行中（未招募）1 期
Multi-center, open-label, non-randomised phase II study to evaluate the activity and tolerability of GW786034 in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists. - VEG20002
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Histologically or cytologically confirmed high or intermediate grade
- •malignant soft tissue sarcoma; most malignant tumors of non organ origin,
- •as well as skin and uterine leiomyosarcoma are included
- •- Measurable disease (according to RECIST)
- •- Relapsed of refractory disease incurable by surgery or radiotherapy
- •- No more than one combination or two single agents chemotherapy
- •regimen for advanced disease; (neo)adjuvant therapy is not counted
- •towards this requirement
- •- No history of leptomeningeal or brain metastases
- •- At least 18 years of age
- •- WHO performance status 0 or 1
- •- Adequate bone marrow function (ANC>1.5 10**9/l, PLA>100 10**9/l
- •- Adequate hepatic function (bilirubin within normal range, SGOP/AST and
- •SGPT/ALT <= 2.5*UNL)
- •- Adequate renal function (creatinine clearance > 50 ml/min, calculated or
- •measured; urine protein excretion <= 500 mg/24h
- •- PT/INR/PTT within 1.2 UNL
- •- LVEF above the lower limit of normal for the institution, based on ECHO
- •or MUGA; no class II, III or IV heart failure (NYHA classification); a patient who has history of class II heart failure and is asymptomatic on treatment may be considered eligible ; no arterial or venous thrombosis, myocardial infarction, unstable angina,
- •cardiac angioplasty or stenting within the last 3 months
- •- No uncontrolled or poorly controlled hypertension (SBP >= 150 mm Hg,
- •DBP >=90 mm Hg). Initiation or adjustment of BP medications is permitted prior to study entry, provided that patient has 3 consecutive BP readings less than 150 / 90 mm Hg each separated by a minimum of 24 hrs.
- •These readings need to be collected prior to registration in the study.
- •- No therapeutic dose warfarin; low molecular weight heparin and prophylactic low dose warfarin are permitted. PT/PTT must meet the above criteria.
- •- Able to swallow and retain oral medication
- •- Women should not be pregnant (negative serum pregnancy test at entry)
- •or lactating, and agree to use contraceptive methods (oral contraceptive are not permitted)
- •- Before patient registration, written informed consent must be given.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The following tumor types are ineligible
- •- Malignant glomus tumors
- •- Embryonal rhabdomyosarcoma
- •- Chondrosarcoma
- •- Osteosarcoma
- •- Ewing tumors / PNET
- •- Gastro-intestinal stromal tumors
- •- Malignant solitary fibrous tumors
- •- Dermofibromatosis sarcoma protuberans
- •- Inflammatory myofibroblastic sarcoma
- •- Neuroblastoma
- •- Malignant mesothelioma
- •- Mixed mesodermal tumors of the uterus
研究者
相似试验
进行中（未招募）
不适用
Multi-center, open-label, non-randomised phase II study to evaluate the activity and tolerability of GW786034 in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists.EUCTR2004-004378-10-BEGlaxoSmithKline Research & Development Ltd148
进行中（未招募）
不适用
Multi-center, open-label, non-randomised phase II study to evaluate the activity and tolerability of GW786034 in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists. - VEG20002Advanced and/or metastatic Soft Tissue SarcomaEUCTR2004-004378-10-HUGlaxoSmithKline Research & Development Ltd148
进行中（未招募）
不适用
Phase II trial of dasatinib in patients with Chronic Myeloid Leukemia in Chronic Phase after prior imatinib treatment.Chronic Myeloid Leukemia in Chronic PhaseMedDRA version: 14.1Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2012-004259-36-ESFundación PETHEMA
进行中（未招募）
不适用
A multicenter, open label, non-randomised phase II study with induction chemotherapy with Cisplatin and 5-fluorouracil as combined with accelerated radiotherapy and Erbitux for locally advanced unresectable squamous cell carcinomaPatient with locally advanced non-resectable squamous cell carcinoma of the head and neck stage III or IV, oral, oropharyngeal, laryngeal or hypopharyngeal cancer, non-resectable.EUCTR2006-002187-25-SERadiumhemmet, Karolinska University Hospital90
进行中（未招募）
不适用
Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capecitabine. - Not applicableMetastatic breast cancer patients after failure to anthracyclines, taxanes and capecitabine.Classification code 10055113EUCTR2004-000572-14-DKAventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)162